Wet Age-related Macular Degeneration is a condition, which results in deterioration of the macula – a tiny spot on the retina – responsible for vision. generally, the macular degeneration starts as a dry type and eventually becomes Wet resulting in a leak in fluid and blood vessels.
According to studies, approximately, 200,000 new cases of Wet AMD are diagnosed with each year in the U.S and Wet AMD result in the cause of 90% of AMD-related severe vision loss.
Also, the prevalence of neovascular AMD in the UK in 2012 was ~2.4%, with an estimated 39,700 new cases diagnosed per year.
Moreover, the number of people affected with Wet AMD will be doubled by 2050, as per the Bright Focus Foundation.
Estimates of the global cost of visual impairment due to age-related macular degeneration are USD 343 billion, including USD 255 billion in direct health care costs.
Wet Age-Related Macular Degeneration Epidemiology (Wet AMD Epidemiology)
DelveInsight’s Wet Age-Related Macular Degeneration (Wet AMD) epidemiology report provides historical as well as forecasted Wet AMD epidemiological stats including prevalence, incidence, diagnosed cases, and total patient pool.
The report lists the share of the current therapy as well as the calculated forecast of the upcoming ones with their individual market share or in case of Wet AMD pipeline products the share they might occupy. The Report also covers current Wet Age-Related Macular Degeneration (Wet AMD) treatment practice/algorithm, market drivers, market barriers and drivers to curate best of the opportunities and assesses the underlying potential of the market.
The wet AMD epidemiology report covers the following geographies:
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
The report provides an overview of the Disease with a detailed understanding of its treatment algorithm providing a thorough understanding of the Wet Age-Related Macular Degeneration (Wet AMD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Moreover, the report also provides Wet AMD Diagnosis segment proffering all the approaches in practice to diagnose the condition, and research undergoing to find a better Wet AMD diagnostics tool.
The data collected is studies from primary as well as secondary research along with valid facts behind the plausible causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Wet Age-related Macular Degeneration Epidemiology section provides a detailed definition of the disease, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Wet Age-Related Macular Degeneration (Wet AMD) in the US, Europe, and Japan. The report covers the detailed information of the Wet Age-Related Macular Degeneration (Wet AMD) epidemiology scenario in seven major countries (US, EU5, and Japan).
Wet macular degeneration approximately accounts 10% of cases, however, results in 90% of legal blindness.
The Wet Age-Related Macular Degeneration (Wet AMD) epidemiology analysis provides insights about historical and current Wet Age-Related Macular Degeneration (Wet AMD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Major pharma companies advancing the Wet Age-related macular degeneration market are Allergan, Bioeq, Alkahest, GrayBug Vision, Eyepoint pharma, Innovent Biologics, Kodiak Sciences, Opthea PanOptica, and Adverum Biotechnologies are steering the Wet AMD market forward.
The emerging therapies such as Abicipar pegol by Allergan, FYB201 by Bioeq, KSI-301 by Kodiak Sciences and several others are going to enter into the Wet AMD therapy market soon.
1. Wet Age-related Macular Degeneration Key Insights
2. Wet Age-related Macular Degeneration Executive Summary of Wet Age-Related Macular Degeneration (Wet AMD)
3. Wet Age-Related Macular Degeneration (Wet AMD): Disease Background and Overview
4. Wet Age-related Macular Degeneration Patient Journey
5. Wet Age-related Macular Degeneration Epidemiology and Patient Population
6. Wet Age-related Macular Degeneration Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Wet Age-related Macular Degeneration Unmet Needs
10. DelveInsight Capabilities
23. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
To know more about the disease, and the research taking place in the field, advancing Wet Age-related macular degeneration market, click here.
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NEVADA 89107
Country: United States